CTP-543 is the deuterated version of FDA approved drug Ruxolitinib, approved for myelofibrosis, and polycythemia vera. Concert Pharmaceuticals plans to address unmet need Alopecia Areata with CTP-543. Proof of concept was confirmed with this academic clinical trial, by Columbia University here JCI. The company will be in a phase 2 clinical trial with around 90 participants beginning in the first quarter of 2017, with readout by the end of 2018. Thank you for reading.
No comments:
Post a Comment